Short answer
TriSalus Life Sciences, Inc. (TLSI) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Dr. Richard Marshall appointed Chief Medical Officer, starting June 29, 2026.
TriSalus Life Sciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Dr. Richard Marshall appointed Chief Medical Officer, starting June 29, 2026
- Annual base salary $525,000 plus $250,000 signing bonus
- Annual incentive opportunity up to 50% of base salary, tied to financial goals and milestones
- Proposed initial equity package: 120,000 stock options and 60,000 restricted stock units
- Additional annual equity eligibility increases potential dilution, subject to Board approval
Item 7.01 · Regulation FD Disclosure
- Dr. Marshall appointed Chief Medical Officer, effective June 29, 2026
- Leadership addition may support clinical development and regulatory execution
- Appointment details and background available in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TriSalus Life Sciences, Inc. 8-K filings
Get the next TLSI 8-K as it lands
Follow TLSI for push alerts, or ask the research agent what this filing means.